JP2012513990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012513990A5 JP2012513990A5 JP2011543458A JP2011543458A JP2012513990A5 JP 2012513990 A5 JP2012513990 A5 JP 2012513990A5 JP 2011543458 A JP2011543458 A JP 2011543458A JP 2011543458 A JP2011543458 A JP 2011543458A JP 2012513990 A5 JP2012513990 A5 JP 2012513990A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- aryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 125000000623 heterocyclic group Chemical group 0.000 claims 62
- 125000003118 aryl group Chemical group 0.000 claims 44
- 125000001072 heteroaryl group Chemical group 0.000 claims 44
- 125000003545 alkoxy group Chemical group 0.000 claims 36
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- -1 COOR1a Chemical group 0.000 claims 22
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000004104 aryloxy group Chemical group 0.000 claims 12
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 12
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- PRULMJKVHATYQP-UHFFFAOYSA-N 4-(quinolin-2-ylmethyl)piperazine-1-carbaldehyde Chemical group C1CN(C=O)CCN1CC1=CC=C(C=CC=C2)C2=N1 PRULMJKVHATYQP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 235000021229 appetite regulation Nutrition 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 0 *c1c(*)nc(*)[n]1C(N(*)*)=O Chemical compound *c1c(*)nc(*)[n]1C(N(*)*)=O 0.000 description 17
- BDVYXMRYPRBKMG-UHFFFAOYSA-N CN(C1CCOCC1)C([n]1cnc(-c2c[n+]([U-])ccc2)c1)=O Chemical compound CN(C1CCOCC1)C([n]1cnc(-c2c[n+]([U-])ccc2)c1)=O BDVYXMRYPRBKMG-UHFFFAOYSA-N 0.000 description 2
- HSLOZRQCLQVPAH-UHFFFAOYSA-N CN(C1CCCCC1)C([n]1cnc(-c2cc[n+](C)cc2)c1)=O Chemical compound CN(C1CCCCC1)C([n]1cnc(-c2cc[n+](C)cc2)c1)=O HSLOZRQCLQVPAH-UHFFFAOYSA-N 0.000 description 1
- OUOUTIJTFIDAHJ-UHFFFAOYSA-N CN(C1CCOCC1)C([n]1cnc(-c2cnccc2)c1)=O Chemical compound CN(C1CCOCC1)C([n]1cnc(-c2cnccc2)c1)=O OUOUTIJTFIDAHJ-UHFFFAOYSA-N 0.000 description 1
- XUEBIYRDHFIJGD-UHFFFAOYSA-N COc(cc(cc1)-c(nc2)c[n]2C(NC2CCCC2)=O)c1F Chemical compound COc(cc(cc1)-c(nc2)c[n]2C(NC2CCCC2)=O)c1F XUEBIYRDHFIJGD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14064008P | 2008-12-24 | 2008-12-24 | |
| US61/140,640 | 2008-12-24 | ||
| US15928109P | 2009-03-11 | 2009-03-11 | |
| US61/159,281 | 2009-03-11 | ||
| US17471209P | 2009-05-01 | 2009-05-01 | |
| US61/174,712 | 2009-05-01 | ||
| US22116609P | 2009-06-29 | 2009-06-29 | |
| US61/221,166 | 2009-06-29 | ||
| US24247209P | 2009-09-15 | 2009-09-15 | |
| US61/242,472 | 2009-09-15 | ||
| PCT/PT2009/000080 WO2010074588A2 (en) | 2008-12-24 | 2009-12-23 | Pharmaceutical compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237957A Division JP2015071622A (ja) | 2008-12-24 | 2014-11-25 | 医薬品 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012513990A JP2012513990A (ja) | 2012-06-21 |
| JP2012513990A5 true JP2012513990A5 (enExample) | 2013-02-14 |
| JP5657566B2 JP5657566B2 (ja) | 2015-01-21 |
Family
ID=42288334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543458A Expired - Fee Related JP5657566B2 (ja) | 2008-12-24 | 2009-12-23 | 医薬品 |
| JP2014237957A Pending JP2015071622A (ja) | 2008-12-24 | 2014-11-25 | 医薬品 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237957A Pending JP2015071622A (ja) | 2008-12-24 | 2014-11-25 | 医薬品 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9353082B2 (enExample) |
| EP (1) | EP2382012A2 (enExample) |
| JP (2) | JP5657566B2 (enExample) |
| KR (1) | KR101715190B1 (enExample) |
| CN (2) | CN102333568B (enExample) |
| AR (1) | AR075111A1 (enExample) |
| AU (1) | AU2009330821B2 (enExample) |
| BR (2) | BRPI0923819B1 (enExample) |
| CA (1) | CA2747784C (enExample) |
| IL (1) | IL213747A (enExample) |
| MX (1) | MX342128B (enExample) |
| NZ (1) | NZ593418A (enExample) |
| RU (1) | RU2553451C2 (enExample) |
| SG (1) | SG172301A1 (enExample) |
| TW (1) | TWI469979B (enExample) |
| WO (1) | WO2010074588A2 (enExample) |
| ZA (1) | ZA201104336B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009314629B2 (en) | 2008-11-14 | 2014-09-25 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| PE20120493A1 (es) | 2009-06-29 | 2012-05-20 | Incyte Corp | Pirimidinonas como inhibidores de pi3k |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| ES2603032T3 (es) * | 2010-07-15 | 2017-02-23 | Bayer Intellectual Property Gmbh | Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas |
| EP2606035B1 (en) * | 2010-07-29 | 2017-09-06 | BIAL - Portela & CA., S.A. | Proces for the synthesis of substituted urea compounds |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| US9108930B2 (en) * | 2011-04-06 | 2015-08-18 | The Scripps Research Institute | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| WO2012168315A1 (en) * | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
| KR20230038593A (ko) | 2011-09-02 | 2023-03-20 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| SG11201500498SA (en) * | 2012-07-24 | 2015-03-30 | Bial Portela & Ca Sa | Urea compounds and their use as enzyme inhibitors |
| BR112015001769A2 (pt) | 2012-07-27 | 2017-08-22 | Bial Portela & Ca Sa | Processo para a síntese de compostos de ureia substituída |
| CN105793247B (zh) * | 2013-07-24 | 2018-03-16 | 比亚尔-珀特拉和Ca股份公司 | 咪唑甲酰胺类及其作为faah抑制剂的用途 |
| CA2919844A1 (en) | 2013-08-01 | 2015-02-05 | Bial - Portela & Ca, S.A. | Urea compounds and their use as faah enzyme inhibitors |
| GB201313903D0 (en) | 2013-08-02 | 2013-09-18 | Bial Portela & Ca Sa | Urea compounds and their use as enzyme inhibitors |
| GB201401198D0 (en) * | 2014-01-24 | 2014-03-12 | Bial Portela & Ca Sa | Process for the syntheis of substituted urea compounds |
| US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| BR112017003918B1 (pt) | 2014-08-29 | 2022-05-03 | Fmc Corporation | Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação |
| CN104292172B (zh) * | 2014-09-12 | 2016-08-17 | 浙江理工大学 | 一种苯并三氮唑类衍生物及其制备方法 |
| PH12017501538B1 (en) | 2015-02-27 | 2024-02-14 | Incyte Holdings Corp | Salts of p13k inhibitor and processes for their preparation |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2017087863A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| CN108601769B (zh) * | 2015-11-20 | 2021-09-03 | H.隆德贝克有限公司 | 吡唑化合物及其制备和使用方法 |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| US10583137B2 (en) | 2015-12-02 | 2020-03-10 | The Scripps Research Institute | Triazole DAGLα inhibitors |
| US11629146B2 (en) | 2016-11-28 | 2023-04-18 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| MX2019008626A (es) * | 2017-01-20 | 2019-09-19 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). |
| EP3571202B1 (en) | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) * | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| LT3630744T (lt) * | 2017-05-23 | 2023-03-10 | H. Lundbeck A/S | Pirazolo magl inhibitoriai |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| AU2018358663B2 (en) * | 2017-11-06 | 2022-09-29 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to AB42 oligomer formation |
| CN111801325A (zh) * | 2018-03-02 | 2020-10-20 | 洛桑大学 | 作为Wnt信号转导通路的抑制剂的吡唑衍生物 |
| CN112423760A (zh) | 2018-05-30 | 2021-02-26 | 普拉克西斯精密药物股份有限公司 | 离子通道调节剂 |
| CN112469418A (zh) | 2018-06-01 | 2021-03-09 | 因赛特公司 | 治疗pi3k相关病症的给药方案 |
| CN108912112A (zh) * | 2018-08-14 | 2018-11-30 | 李敬敬 | 一种化合物、制备方法以及其在治疗疼痛中的应用 |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US12268672B2 (en) | 2018-10-23 | 2025-04-08 | Japan Science And Technology Agency | PPARδ activator |
| AU2019382504B2 (en) * | 2018-11-20 | 2024-11-14 | Sironax Ltd | Cyclic ureas |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| EP4387617A4 (en) * | 2021-08-18 | 2025-10-29 | Univ California | ACID CERAMIDASE INHIBITORS AND THEIR USES |
| CN115707699B (zh) * | 2021-08-18 | 2025-08-19 | 中国医学科学院医药生物技术研究所 | 一组抗骨质疏松的化合物及其应用 |
| US12234205B1 (en) | 2024-05-22 | 2025-02-25 | King Saud University | Sulfonylhydrazide derivatives as anticancer agents |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3248398A (en) * | 1961-01-05 | 1966-04-26 | Bayer Ag | Substituted ureas |
| GB1408877A (en) * | 1971-12-07 | 1975-10-08 | Boots Co Ltd | Substituted imidazoles and their use as pesticides |
| US3940484A (en) * | 1971-12-07 | 1976-02-24 | The Boots Company Limited | Insecticidal compositions and methods of combatting insects using substituted imidazoles |
| US3932444A (en) * | 1972-04-28 | 1976-01-13 | E. I. Du Pont De Nemours & Co. | 4-Imidazolylsulfonylimidazoles |
| CA1035188A (en) * | 1974-08-15 | 1978-07-25 | Eastman Kodak Company | Blocked development restrainers |
| DE2834879A1 (de) * | 1978-08-07 | 1980-02-21 | Schering Ag | 1,2,3-triazolcarbonsaeureamide, verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel |
| CA1126999A (en) * | 1978-10-20 | 1982-07-06 | Michael J. Simons | Use of azole compounds with a n,n disubstituted carbamoyl group on a ring nitrogen as development restrainer precursors in photographic elements |
| GB8426367D0 (en) * | 1984-10-18 | 1984-11-21 | Shell Int Research | Heteroaromatic ether herbicides |
| FR2579596B1 (fr) | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
| JPH0753716B2 (ja) | 1986-07-02 | 1995-06-07 | 吉富製薬株式会社 | イミダゾ−ルカルボキサミド誘導体 |
| DD295852A5 (de) * | 1988-07-18 | 1991-11-14 | Arzneimittelwerk Dresden Gmbh,De | Verfahren zur herstellung von acylureido-benzylpenicillinen und deren salzen |
| JPH02124559A (ja) * | 1988-11-02 | 1990-05-11 | Fuji Photo Film Co Ltd | ネガ型ハロゲン化銀写真感光材料 |
| US4942248A (en) * | 1988-12-01 | 1990-07-17 | Ppg Industries, Inc. | Tertiary-alkyl esters of 1H-benzotriazole-1-carboxylic acids |
| JPH03246206A (ja) * | 1990-02-21 | 1991-11-01 | Sumitomo Chem Co Ltd | トリハロイミダゾール誘導体を有効成分とするゴキブリ用殺虫剤 |
| JPH0559017A (ja) * | 1990-10-26 | 1993-03-09 | Ube Ind Ltd | １，２，３−トリアゾール誘導体、その製法及び有害生物防除剤 |
| US5656762A (en) | 1990-12-28 | 1997-08-12 | Neurogen Corporation | 4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands |
| FR2671083B1 (fr) * | 1990-12-31 | 1994-12-23 | Inst Nat Sante Rech Med | Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques. |
| JPH0649041A (ja) * | 1992-07-28 | 1994-02-22 | Mitsubishi Petrochem Co Ltd | カルバモイルトリアゾール誘導体、それを有効成分とする除草剤およびその製造方法 |
| US6262093B1 (en) * | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
| US5798374A (en) * | 1995-06-07 | 1998-08-25 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith |
| JPH11338100A (ja) * | 1998-05-22 | 1999-12-10 | Fuji Photo Film Co Ltd | 記録材料 |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| JP2001302640A (ja) * | 2000-04-19 | 2001-10-31 | Tokuyama Corp | カルボニルジアゾール誘導体の製造方法 |
| US6472133B1 (en) * | 2000-06-13 | 2002-10-29 | Eastman Kodak Company | Silver halide element with improved high temperature storage |
| US6372421B1 (en) * | 2000-06-13 | 2002-04-16 | Eastman Kodak Company | Photothermographic imaging element having improved contrast and methods of image formation |
| JP2004509949A (ja) * | 2000-09-26 | 2004-04-02 | ザ ユニバーシティ オブ アリゾナ ファウンデーション | 化合物および癌またはウイルス性感染症治療におけるその使用方法 |
| US20020128232A1 (en) * | 2000-10-12 | 2002-09-12 | Henderson Scott A. | Heterocyclic angiogenesis inhibitors |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| US6727364B2 (en) * | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| JP2003005323A (ja) * | 2001-06-20 | 2003-01-08 | Konica Corp | 熱現像写真感光材料及び画像形成方法 |
| US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| PL373156A1 (en) * | 2001-12-14 | 2005-08-22 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| JP2003327532A (ja) * | 2002-05-10 | 2003-11-19 | Takeda Chem Ind Ltd | ペプチダーゼ阻害剤 |
| MXPA05003715A (es) * | 2002-10-07 | 2005-09-30 | Univ California | Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida. |
| AU2003275493A1 (en) * | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
| US7208504B2 (en) | 2002-10-12 | 2007-04-24 | Sanofi-Aventis Deutschland Gmbh | Bicyclic inhibitors of hormone sensitive lipase |
| AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| PE20050226A1 (es) | 2003-06-04 | 2005-05-18 | Aventis Pharma Sa | Productos aril-heteroaromaticos y composiciones que los contienen |
| WO2005014576A1 (ja) * | 2003-08-12 | 2005-02-17 | Takeda Pharmaceutical Company Limited | イソキノリノン誘導体、その製造法および用途 |
| EP1794130A1 (en) * | 2004-09-20 | 2007-06-13 | Biolipox AB | Pyrazole compounds useful in the treatment of inflammation |
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| EP2937341B1 (en) * | 2004-12-30 | 2017-07-05 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
| US7541359B2 (en) * | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| TW200738701A (en) * | 2005-07-26 | 2007-10-16 | Du Pont | Fungicidal carboxamides |
| US7884119B2 (en) * | 2005-09-07 | 2011-02-08 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as Axl inhibitors |
| DE102005049954A1 (de) * | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| DE102005049953A1 (de) * | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| TW200732320A (en) * | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| CA2665804A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| FR2915199B1 (fr) * | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
| FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| FI20075264A0 (fi) * | 2007-04-18 | 2007-04-18 | Kuopion Yliopisto | Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina |
| CA2932121A1 (en) * | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009117444A1 (en) | 2008-03-17 | 2009-09-24 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| JP5620365B2 (ja) * | 2008-03-21 | 2014-11-05 | エンソン インコーポレイテッド | 多官能分子システムを用いた積層体への金属の接着促進 |
| ES2937247T3 (es) * | 2019-05-02 | 2023-03-27 | Teepack Spezialmaschinen Gmbh & Co Kg | Dispositivo y procedimiento para fabricar una bolsa provista de un envoltorio que contiene un material apto para infusión |
-
2009
- 2009-12-23 TW TW98144476A patent/TWI469979B/zh not_active IP Right Cessation
- 2009-12-23 RU RU2011129416/04A patent/RU2553451C2/ru active
- 2009-12-23 CN CN200980157449.6A patent/CN102333568B/zh not_active Expired - Fee Related
- 2009-12-23 BR BRPI0923819-0A patent/BRPI0923819B1/pt not_active IP Right Cessation
- 2009-12-23 BR BR122013027950A patent/BR122013027950A2/pt not_active Application Discontinuation
- 2009-12-23 JP JP2011543458A patent/JP5657566B2/ja not_active Expired - Fee Related
- 2009-12-23 CN CN201510829064.7A patent/CN105399731A/zh active Pending
- 2009-12-23 EP EP09801307A patent/EP2382012A2/en not_active Withdrawn
- 2009-12-23 CA CA2747784A patent/CA2747784C/en active Active
- 2009-12-23 US US13/141,205 patent/US9353082B2/en not_active Expired - Fee Related
- 2009-12-23 NZ NZ593418A patent/NZ593418A/xx not_active IP Right Cessation
- 2009-12-23 AU AU2009330821A patent/AU2009330821B2/en not_active Ceased
- 2009-12-23 AR ARP090105108A patent/AR075111A1/es not_active Application Discontinuation
- 2009-12-23 MX MX2011006643A patent/MX342128B/es active IP Right Grant
- 2009-12-23 WO PCT/PT2009/000080 patent/WO2010074588A2/en not_active Ceased
- 2009-12-23 SG SG2011045465A patent/SG172301A1/en unknown
- 2009-12-23 KR KR1020117017329A patent/KR101715190B1/ko not_active Expired - Fee Related
-
2011
- 2011-06-10 ZA ZA2011/04336A patent/ZA201104336B/en unknown
- 2011-06-23 IL IL213747A patent/IL213747A/en not_active IP Right Cessation
-
2014
- 2014-11-25 JP JP2014237957A patent/JP2015071622A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513990A5 (enExample) | ||
| CA2493225A1 (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| JP2006504658A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2018515555A5 (enExample) | ||
| JP2011505347A5 (enExample) | ||
| JP2019513770A5 (enExample) | ||
| JP2013513613A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2018509418A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| CA2476983A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma | |
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| JP2015508103A5 (enExample) | ||
| CA2566544A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| JP2013544860A5 (enExample) | ||
| MX2008009413A (es) | Heterociclos como agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia. | |
| JP2010515750A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2014505723A5 (enExample) | ||
| JP2017502063A5 (enExample) | ||
| GB0417910D0 (en) | Organic compounds | |
| JP2007500222A5 (enExample) |